Organization | Radiation Therapy Oncology Group

Radiation Therapy Oncology Group Report issue

Foundation Phase 1 Phase 2 Phase 3

Founded: Philadelphia PA United States (1968)

Organization Overview

First Clinical Trial

1990

NCT03722355

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2015

Timeline

NOW

Now

Alternative names

Radiation Therapy Oncology Group

Active Ingredients

Drugs in Phase 3 Trials (58)

125-iodine (5 trials)

amifostine (ethyol) (2 trials)

bicalutamide (casodex) (9 trials)

buserelin (receptal) (3 trials)

calcium (1 trial)

calcium carbonate (1 trial)

calcium citrate (1 trial)

calcium glucarate (1 trial)

carboplatin (paraplatin) (13 trials)

carmustine (bicnu) (5 trials)

cetuximab (erbitux) (8 trials)

cisplatin (platinol) (50 trials)

docetaxel (taxotere) (8 trials)

doxorubicin (Doxil) (5 trials)

epoetin (Epogen) (1 trial)

erlotinib (tarceva) (2 trials)

estramustine (emcyt) (2 trials)

etoposide (vepesid) (8 trials)

Filgrastim (neupogen) (3 trials)

fluorouracil (efudex) (19 trials)

flutamide (eulexin) (11 trials)

gemcitabine (gemzar) (12 trials)

gonadorelin (factrel) (1 trial)

goserelin (zoladex) (8 trials)

ketoconazole (nizoral) (1 trial)

leucovorin (4 trials)

leuprolide (lupron) (6 trials)

levamisole (ergamisol) (1 trial)

lomustine (3 trials)

memantine (namenda) (1 trial)

mitomycin (mutamycin) (3 trials)

octreotide (sandostatin) (1 trial)

orteronel (1 trial)

paclitaxel (taxol) (30 trials)

palifermin (Kepivance) (1 trial)

palladium (1 trial)

pentosan polysulfate sodium (elmiron) (1 trial)

pilocarpine (ocusert) (2 trials)

prednisone (meticorten) (1 trial)

procarbazine (matulane) (3 trials)

samarium-153 lexidronam (quadramet) (2 trials)

sargramostim (leukine) (12 trials)

shark cartilage extract ae-941 (1 trial)

sorafenib (nexavar) (1 trial)

strontium-89 (1 trial)

tadalafil (cialis) (1 trial)

talc (sclerosol) (1 trial)

tamoxifen (nolvadex) (2 trials)

temozolomide (temodar) (16 trials)

thalidomide (Thalomid) (2 trials)

triptorelin (Trelstar) (3 trials)

vinblastine (velban) (3 trials)

vincristine (oncovin) (3 trials)

vinorelbine (navelbine) (2 trials)

vitamin d3 (2 trials)

warfarin (coumadin) (1 trial)

zoledronic acid (zometa) (2 trials)

Drugs in Phase 2 Trials (33)

103-palladium (1 trial)

bevacizumab (avastin) (6 trials)

bleomycin (blenoxane) (1 trial)

capecitabine (xeloda) (6 trials)

captopril (capoten) (1 trial)

celecoxib (celebrex) (2 trials)

conatumumab (1 trial)

cytarabine (cytosar-u) (1 trial)

dacarbazine (dtic-dome) (3 trials)

depatuxizumab mafodotin (1 trial)

everolimus (zortress) (1 trial)

fludeoxyglucose f-18 (1 trial)

gefitinib (iressa) (1 trial)

ifosfamide (ifex) (4 trials)

imatinib (gleevec) (1 trial)

irinotecan (Camptosar) (5 trials)

lapatinib (tykerb) (1 trial)

lidocaine (xylocaine) (1 trial)

manuka honey (1 trial)

melatonin (1 trial)

mesna (mesnex) (1 trial)

motexafin gadolinium (1 trial)

naltrexone (revia) (2 trials)

oxaliplatin (eloxatin) (2 trials)

oxycodone (oxycontin) (1 trial)

panitumumab (vectibix) (1 trial)

rituximab (rituxan) (2 trials)

romiplostim (nplate) (2 trials)

trastuzumab (herceptin) (1 trial)

vandetanib (caprelsa) (1 trial)

veliparib (1 trial)

zarnestra (1 trial)

Drugs in Phase 1 Trials (2)

ganitumab (1 trial)

soybean (1 trial)

Drugs in Other Trials (1)

sildenafil (viagra) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 3)

Adenocarcinoma, Clear Cell (Phase 2)

Adenocarcinoma of Lung (Phase 3)

Anus Neoplasms (Phase 3)

Astrocytoma (Phase 3)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Adenosquamous (Phase 2)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma in Situ (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Carcinoma, Transitional Cell (Phase 2)

Carcinoma, Verrucous (Phase 3)

Central Nervous System Neoplasms (Phase 3)

Colorectal Neoplasms (Phase 2)

Cystadenocarcinoma, Serous (Phase 2)

Deglutition Disorders (Phase 2)

Diarrhea (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 3)

Endometrial Neoplasms (Phase 3)

Enteritis (Phase 3)

Erectile Dysfunction (Phase 3)

Esophageal Neoplasms (Phase 3)

Esophagitis (Phase 2)

Fibrosis (Phase 2)

Gastrointestinal Stromal Tumors (Phase 2)

Glioblastoma (Phase 3)

Glioma (Phase 3)

Gliosarcoma (Phase 3)

Head and Neck Neoplasms (Phase 3)

Laryngeal Diseases (Phase 3)

Laryngeal Neoplasms (Phase 3)

Liver Neoplasms (Phase 3)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 2)

Mucositis (Phase 3)

Nasopharyngeal Carcinoma (Phase 2)

Nasopharyngeal Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 3)

Nervous System Neoplasms (Phase 3)

Neurotoxicity Syndromes (Phase 3)

Oligodendroglioma (Phase 3)

Oropharyngeal Neoplasms (Phase 3)

Osteoporosis (Phase 3)

Pancreatic Neoplasms (Phase 3)

Pleural Effusion (Phase 3)

Pleural Effusion, Malignant (Phase 3)

Precancerous Conditions (Phase 3)

Prostatic Neoplasms (Phase 3)

Radiation Pneumonitis (Phase 2)

Rectal Neoplasms (Phase 3)

Salivary Gland Neoplasms (Phase 2)

Sarcoma (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Stomach Neoplasms (Phase 2)

Stomatitis (Phase 3)

Tongue Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 3)

Xerostomia (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 143
# of Trial APIs: 94